2024.11.13

Syros Pharmaceuticals Inc., announced Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression.

2024.08.14

Syros Pharmaceuticals Inc., has announced that it will no longer be enrolling new patients in its clinical trial for AML.

2024.04.10

FDA has granted Fast Track Designation to Tamibarotene for the treatment of Newly Diagnosed Unfit AML.

2023.01.27

FDA has granted Fast Track Designation to Tamibarotene for the treatment of higher risk MDS.

2022.08.04

EMA committee issued Positive Opinion to TM-411 for MDS on Orphan Drug Designation.

2022.07.11

Approval of use patent for TM-411 as a cancer stem cell proliferation inhibitor by European Patent Office.

2022.04.13

Research group led by researchers at Dept. of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, published in"Oncogene" on the effect of TM-411 to ameliorate the susceptibility of chemotherapy to pancreatic cancer.

2022.02.03

FDA designated TM-411 for MDS as an Orphan Drug.

2021.09.10

First patient enrolled in Phase II clinical trial of TM-411 in triplet combination with venetoclax and azacitidine for AML in US.

2021.05.10

First patient enrolled in phaseⅢ clinical trial of TM-411 in combination with azacitidine for higher-risk MDS in US.

2021.01.12

Reached an agreement with Syros Pharmaceuticals Inc., to be granted for the Biomarker License.

2021.01.12

Reached agreement with Syros Pharmaceuticals Inc., to add the Southern America & Oceania regions in the territory in the license agreement dated Sept. 2015.

2018.08.08

EMA designated TM-411 for AML as an Orphan Drug

2017.08.23

FDA designated TM-411 for AML as an Orphan Drug

2016.09.22

First patient enrolled in phase II clinical trial of TM-411 in acute myeloid leukemia or myelodysplastic syndrome in US.

2016.06.01

FDA Accepts IND to Advance TM-411 submitted as SY-1425 by Syros into Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

2015.09.11

TMRC reached a license agreement with Syros Pharmaceuticals to develop and commercialize TM-411 in North America and Europe for cancer.

2015.04.10

Investigator initiated Phase I study of TM-411 in the relapsed/refractory pediatric solid tumor was started at the National Cancer Center Hospital in Tokyo.

2014.07.18

TMRC reached a collaboration agreement with Children's Hospital Los Angeles (CHLA) to develop and commercialize TM-411 in neutropenia

2014.06.10

License Agreement granted to CytRx Corporation (CytRx) concerning exclusive development and sale of TM-411 in North American and European territory is terminated.

2014.06.05

TMRC has concluded a license agreement with a Japanese company, Ohara Pharmaceutical Co., Ltd., to license out Tamibarotene , anticancer drug including pediatric cancer, in Japanese territory.

2014.04.04

Approval of formulation patent for TM-411 capsule by JAPAN Patent & Trademark.

2013.03.04

Move Head office to Shinjyuku-ku, Tokyo.

2012.07.12

License Agreement granted to ZERIA Pharmaceutical Co.,Ltd.(ZERIA) concerning joint development and exclusive manufacture and sale of TM-411 in the indication of hepatocellular carcinoma (HCC) in Japanese territory is terminated.

2012.06.27

Approval of formulation patent for TM-411 capsule by US Patent & Trademark Office.

2012.06.26

License Agreement granted to LOTUS PHARMACEUTICAL Co.,Ltd. concerning exclusive manufacture and sale of TM-411 in the indication of acute promyelocytic leukemia (APL) in Chinese territory is terminated. TMRC has returned right of such manufacture and sale of TM-411 to TOKO PHARMACEUTICAL CO.,Ltd. (TOKO), TMRC's licensor, for TOKO succeed such manufacture and sale of TM-411

2011.10.31

Move Head office to Minato-ku, Tokyo.

2011.03.22

Exercising of First Refusal Right(FRR)by CytRx Corporation for the treatment of Non-small-cell lung cancer(NSCLC)

2011.02.07

TMRC has concluded a Basic Agreement for business alliance of TM-411(Tamibarotene) on February 2, 2011 with EPS and LOTUS to sell product (TM-411) for the treatment of APL in China.

2010.07.02

A PhaseII study of Tamibarotene, for the treatment of HCC (Licensed to Zeria Pharmaceuticals) will be initiated.

2009.03.16

Spinning off CRO business and established as a subsidiary company, then transfer 100% of stocks to Sugi Medical Co., Ltd.

2009.02.13

Starting the Phase II clinical trial of TM-411 for the treatment of refractory acute promyelocytic leukemia (APL) in China.

2008.09.19

INNOVIVE Pharmaceuticals, Inc., has been acquired and merged by a US Company CytRx Corporation.

2008.09.02

Zeria Pharmaceutical co. has initiated Phase I/II clinical trial evaluating oral Tamibarotene, anticancer drug, for the treatment of hepatocellular carcinoma(HCC).

2007.11.22

INNOVIVE Pharmaceuticals, Inc. announced the first patient has been treated in a pivotal Phase II clinical trial evaluating oral Tamibarotene, anticancer drug for the treatment of refractory acute promyelocytic leukemia (APL).

2007.11.13

TMRC has concluded a license agreement with a Japanese company, LOTUS PHARMACEUTICAL Co., LTD. (former Order-Made Souyaku Co., Ltd.) , to License out Tamibarotene , anticancer drug , in Chinese territory.

2007.10.17

Food and Drug Administration has granted orphan drug designation to the company's drug candidate Tamibarotene ,anticancer drug, for the treatment of adult patients with relapsed of refractory acute promyelocytic leukemia (APL) following treatment with all-tans-retinoic acid (ATRA) and arsenic trioxide.

2007.09.11

TMRC has concluded a license agreement with a US company, INNOVIVE Pharmaceuticals, Inc., to License out Tamibarotene , anticancer drug , in European territory.

2007.08.28

TMRC has concluded a license agreement with a Japanese company, Zeria Pharmaceutical co., Ltd., to License out Tamibarotene , anticancer drug, for the treatment of hepatocellular carcinoma(HCC).

2007.08.08

Food and Drug Administration has granted Fast Track Designation for Tamibarotene, anticancer drug, for the treatment of acute promyelocytic leukemia. A pivotal Phase II study of Tamibarotene will be initiated this summer.

2006.12.08

TMRC has concluded a license agreement with a US company, INNOVIVE Pharmaceuticals, to License out Tamibarotene , anticancer drug , in North American territory.